Search results for "Immunity"

showing 10 items of 1537 documents

Biomarkers for glaucoma: from the lab to the clinic

2017

Glaucoma, a leading cause of irreversible blindness worldwide, is often not diagnosed until many years after disease onset. Early and objective diagnostic measures are yet missing. Besides the main risk factor, an elevated intraocular pressure (IOP), age, sex, and ethnicity are known to affect disease progression and severity. Furthermore, oxidative stress, elevated glutamate concentrations, and an autoimmune component are considered possible risk factors. We could identify several potential proteomic biomarkers in glaucoma and examine distinct changes in the glaucomatous human retina proteome. Using an experimental autoimmune glaucoma animal (EAG) model we could demonstrate an IOP-independ…

ProteomicsRetinal Ganglion CellsIntraocular pressuremedicine.medical_specialtygenetic structuresSwineGlaucomaAutoimmunitymedicine.disease_causeRetinal ganglionRetinaAutoimmunity03 medical and health sciences0302 clinical medicineOphthalmologyMedicineAnimalsHumansIntraocular PressureAutoantibodiesRetinabusiness.industryAutoantibodyGlaucomamedicine.diseaseeye diseasesCambridge Ophthalmological SymposiumOphthalmologyDisease Models Animalmedicine.anatomical_structureImmunoglobulin GImmunology030221 ophthalmology & optometryOptic nerveDisease ProgressionBiomarker (medicine)sense organsMicrogliabusiness030217 neurology & neurosurgeryBiomarkers
researchProduct

Serum and antibodies of glaucoma patients lead to changes in the proteome, especially cell regulatory proteins, in retinal cells.

2012

PURPOSE: Previous studies show significantly specifically changed autoantibody reactions against retinal antigens in the serum of glaucoma and ocular hypertension (OHT) patients in comparison to healthy people. As pathogenesis of glaucoma still is unknown the aim of this study was to analyze if the serum and antibodies of glaucoma patients interact with neuroretinal cells. METHODS: R28 cells were incubated with serum of patients suffering from primary open angle glaucoma (POAG), normal tension glaucoma (NTG) or OHT, POAG serum after antibody removal and serum from healthy people for 48 h under a normal or an elevated pressure of 15000 Pa (112 mmHg). RGC5 cells were additionally incubated wi…

ProteomicsRetinal Ganglion CellsSerumProteomegenetic structuresOcular hypertensionGlaucomalcsh:MedicineAutoimmunityPathogenesischemistry.chemical_compoundMolecular Cell Biologylcsh:ScienceCellular Stress ResponsesMultidisciplinarySpectrometric Identification of ProteinsbiologyNeurodegenerative DiseasesBlood proteinsSignaling CascadesNeurologyMedicineRetinal DisordersElectrophoresis Polyacrylamide GelAntibodyGlaucoma Open-AngleRetinal NeuronsSignal TransductionResearch ArticleSpectrometry Mass Electrospray IonizationImmunologyImmunoglobulinsPeptide MappingAntibodiesStress Signaling CascadeCell LineAntigenmedicinePressureAnimalsHumansBiologylcsh:RAutoantibodyRetinalGlaucomamedicine.diseaseeye diseasesRatsOphthalmologychemistrySpectrometry Mass Matrix-Assisted Laser Desorption-IonizationImmunologybiology.proteinOcular HypertensionClinical Immunologylcsh:Qsense organsChromatography LiquidPLoS ONE
researchProduct

Common Factors in Neurodegeneration: A Meta-Study Revealing Shared Patterns on a Multi-Omics Scale

2020

Neurodegenerative diseases such as Alzheimer&rsquo

Proteomicsamyotrophic lateral sclerosisParkinson's diseaseDatabases FactualProteomeDiseaseComputational biologyBiologyPolymorphism Single NucleotideArticleTranscriptomeImmune systemHuntington's diseaseAlzheimer DiseasemedicineHumansbiochemistryAmyotrophic lateral sclerosislcsh:QH301-705.5GeneAlzheimer’s disease ; multi-omics ; neurodegeneration ; Huntington’s disease ; Parkinson’s disease ; amyotrophic lateral sclerosisNeurodegenerationneurodegenerationNeurodegenerative DiseasesParkinson DiseaseGenomicsGeneral Medicinemulti-omicsmedicine.diseaseImmunity HumoralGene OntologyHuntington Diseaselcsh:Biology (General)Parkinson’s diseaseTranscriptomeAlzheimer’s diseaseGenome-Wide Association StudyHuntington’s disease
researchProduct

Speculation on whether a vaccine against cryptosporidiosis is a reality or fantasy

1999

In this paper the authors question whether the development of a vaccine against cryptosporidiosis could be taken into consideration. The necessity and feasibility of such a vaccine for human and veterinary application is discussed. Developmental stages within the life cycle of the parasite that might act as possible targets for vaccine development are summarised, as well as the target antigens offered by molecular biology and immunology studies. Vaccination trials against cryptosporidiosis carried out so far, including the active and passive immunisation approach, are also overviewed. It seems that with respect to a Cryptosporidium vaccine two target groups can be considered: children of th…

Protozoan VaccinesRuminantCloneProtozoan ProteinsTarget groupsCryptosporidiosisRuminant animalArticleImmunityAnimalsHumansImmune responseSpeculationCryptosporidium parvumbiologyCryptosporidiumbiology.organism_classificationVaccinationInfectious DiseasesCryptosporidium parvumAntigenApical organellesPassive immunisationImmunologyParasitologyVaccineHumanInternational Journal for Parasitology
researchProduct

Expression of B-Cell Activating Factor Enhances Protective Immunity of a Vaccine against Pseudomonas aeruginosa

2009

ABSTRACT B-cell activating factor (BAFF), a member of the TNF family, is a potent cytokine with stimulatory effects on B and T cells. To evaluate the potential of transient overexpression of BAFF to enhance vaccine immunogenicity, a replication-deficient adenovirus expressing full-length murine BAFF (AdBAFF) was tested in a mouse vaccine model against Pseudomonas aeruginosa . When coadministered with heat-killed P. aeruginosa , AdBAFF mediated a significant increase in anti- P. aeruginosa- specific serum and lung mucosal antibodies and resulted in improved protection against a lethal respiratory challenge with P. aeruginosa . This effect was independent of the site of administration of AdBA…

Pseudomonas Vaccinesmedicine.medical_treatmentGenetic VectorsImmunologyBiologymedicine.disease_causeMicrobiologyAdenoviridaeMicrobiologyMiceImmune systemAdjuvants ImmunologicImmunityB-Cell Activating FactorPneumonia BacterialmedicineAnimalsB-cell activating factorImmunity MucosalPseudomonas aeruginosaAntibodies BacterialSurvival AnalysisMice Inbred C57BLInfectious DiseasesCytokineVaccines InactivatedImmunizationMicrobial Immunity and VaccinesPseudomonas aeruginosaImmunologybiology.proteinFemaleParasitologyAntibodyAdjuvantInfection and Immunity
researchProduct

Humoral autoreactivity directed against surfactant protein-A (SP-A) in rheumatoid arthritis synovial fluids.

2000

SUMMARY SP-A is found principally in the lung, and has been associated with lamellar bodies also found in the synovial joint. Both SP-A and C1q contain collagen-like regions, and SP-A and C1q have some structural similarities, both having a globular head region and a collagen-like tail. Here we are able to show that (i) autoreactivity to SP-A, as expressed by IgG and IgM autoantibodies, is present in synovial fluid (SF) isolated from patients with rheumatoid arthritis (RA); (ii) in absorption experiments only a limited degree of cross-reactivity between autoantibodies reactive with C1q and SP-A is observed; (iii) there is no cross-reactivity between autoantibodies reactive with type II coll…

Pulmonary Surfactant-Associated ProteinsKnee JointProteolipidsImmunologyType II collagenchemical and pharmacologic phenomenamedicine.disease_causeAutoantigensImmunoglobulin GAutoimmunityArthritis RheumatoidRheumatic DiseaseAntigenSynovial jointSynovial FluidmedicineImmunology and AllergySynovial fluidAnimalsHumansskin and connective tissue diseasesAutoantibodiesbiologyPulmonary Surfactant-Associated Protein AChemistryComplement C1qAutoantibodyPulmonary Surfactantsmedicine.anatomical_structureImmunoglobulin MImmunoglobulin MImmunoglobulin GImmunologybiology.proteinBinding Sites AntibodyCollagenPeptidesChickensDimerizationClinical and experimental immunology
researchProduct

2021

PURPOSE Patients with chronic spontaneous urticaria (CSU) have an increased risk for comorbid autoimmune diseases. In this retrospective multicenter study of CSU patients, we evaluated clinical and laboratory features of CSU associated with a higher risk of comorbid autoimmune diseases. METHODS We analyzed records of CSU patients (n = 1,199) for a history or presence of autoimmune diseases. Patients were diagnosed with type IIb autoimmune CSU (aiCSU) if all 3 tests were positive: autologous serum skin test (ASST), basophil histamine release assay (BHRA) and/or basophil activation test (BAT), and IgG autoantibodies against FceRIα/IgE detected by immunoassay. RESULTS Twenty-eight percent of C…

Pulmonary and Respiratory MedicineAutoimmune diseaseAnti-nuclear antibodybusiness.industryImmunologyAutoantibodyVitiligoOmalizumabmedicine.diseasemedicine.disease_causeThyroiditisAutoimmunityAutoimmune thyroiditis03 medical and health sciences0302 clinical medicine030228 respiratory systemImmunologymedicineImmunology and Allergy030223 otorhinolaryngologybusinessmedicine.drugAllergy, Asthma & Immunology Research
researchProduct

Against all odds: anti-IgE for intrinsic asthma?

2013

For many years, pathogenetic concepts and the results of clinical trials supported the view that anti-IgE treatment is specifically effective in allergic asthma. However, there is now growing clinical and mechanistic evidence suggesting that treatment with the anti-IgE antibody omalizumab can be effective in patients with intrinsic asthma. Therefore, large and well-controlled clinical trials with anti-IgE are urgently warranted in patients with intrinsic asthma. In addition, there is a need to find new biomarkers which can identify patients with asthma who respond to anti-IgE treatment.

Pulmonary and Respiratory MedicineIntrinsic FactorChest ClinicOmalizumabOmalizumabAsthma PharmacologyImmunoglobulin EAntibodies Monoclonal HumanizedAnti-asthmatic AgentOddsmedicineHumansAnti-Asthmatic Agents1506AsthmaIntrinsic factorbiologybusiness.industrymedicine.diseaseAsthmaImmunity Innaterespiratory tract diseasesAntibodies Anti-IdiotypicClinical trialAsthma MechanismsIntrinsic asthmaImmunologybiology.proteinDisease Progressionbusinessmedicine.drugThorax
researchProduct

The Non-neuronal cholinergic system: an emerging drug target in the airways.

2001

The non-neuronal cholinergic system is widely expressed in human airways. Choline acetyltransferase (ChAT) and/or acetylcholine are demonstrated in more or less all epithelial surface cells (goblet cells, ciliated cells, basal cells), submucosal glands and airway smooth muscle fibres. Acetylcholine is also demonstrated in the effector cells of the immune system (lymphocytes, macrophages, mast cells). Epithelial, endothelial and immune cells express nicotinic and muscarinic receptors. Thus the cytomolecule acetylcholine can contribute to the regulation of basic cell functions via auto-/paracrine mechanisms (proliferation, differentiation, ciliary activity, secretion of water, ions and mucus,…

Pulmonary and Respiratory MedicineLung Diseasesmedicine.medical_specialtyInflammationBiologyReceptors NicotinicCholine O-AcetyltransferaseImmune systemInternal medicineMuscarinic acetylcholine receptorMuscarinic acetylcholine receptor M5medicineHomeostasisHumansPharmacology (medical)InflammationImmunity CellularBiochemistry (medical)Muscarinic acetylcholine receptor M3Epithelial CellsMuscle SmoothCholine acetyltransferaseReceptors MuscarinicAcetylcholineCell biologyNicotinic agonistEndocrinologyAntibody Formationmedicine.symptomAcetylcholinemedicine.drugPulmonary pharmacologytherapeutics
researchProduct

An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small …

2007

Mutations of the ras gene have been reported in 20-40% of NSCLC patients. If present, they are critical for the malignant phenotype of these tumors. Therefore, targeting them by specific vaccination is a promising therapeutic approach. In a clinical trial we screened for ras mutations in patients with NSCLC. Patients with ras-positive tumors were immunized six times intradermally with a mixture of seven peptides representing the most common ras mutations. Objectives of the study were the feasibility, efficacy and safety of the vaccination. In addition, the induction of a specific immune reaction was investigated by DTH tests, and the induction of peptide-specific T cells was tested in ex vi…

Pulmonary and Respiratory MedicineOncologyMaleCancer Researchmedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentT-LymphocytesCancer VaccinesImmune systemInternal medicineCarcinoma Non-Small-Cell LungCarcinomaMedicineHumansLung cancerCodonAgedNeoplasm StagingImmunity Cellularbusiness.industryImmunogenicityRas PeptideVaccinationGranulocyte-Macrophage Colony-Stimulating FactorImmunotherapyMiddle Agedmedicine.diseaseCombined Modality TherapyPeptide FragmentsRecombinant ProteinsVaccinationOncologyImmunologyMutationras ProteinsFemaleImmunotherapybusinessEx vivoLung cancer (Amsterdam, Netherlands)
researchProduct